In recent years, the call for transparency in pharmaceutical pricing has gained momentum among policymakers and stakeholders. Following a resolution of the 72nd World Health Assembly and the establishment of the Oslo Medicines Initiative, there has been a concerted push for greater transparency in pricing practices. However, the exact scope of transparency measures remains unclear. Key questions persist regarding which prices and for which medicines should be disclosed, the conditions under which countries are willing to share this information, and the barriers hindering such efforts. To clarify these issues and advance the policy debate, the OECD examined the feasibility of sharing medicine price information across countries. A country survey was conducted to explore the willingness, expectations, and motives of governments and payers for sharing information on medicine prices. This report presents the key findings derived from the survey and concludes with an assessment of the feasibility of sharing net medicine price information among OECD countries.
